Systems and methods for the preparation of vaccines utilizing predictably inactivated pathogens

1. A method for producing an immunogenic composition comprising:

(a) neutering an intact pathogenic source, wherein neutering the pathogenic source involves:

destroying the genetic material of the pathogenic source by varying a dosage and/or a wavelength of UV-C radiation such that the pathogenic source is unable to reproduce or cause infection while leaving intact at least some or all of its membrane or structural proteins as antigens; and

(b) aliquoting the neutered pathogenic source into containers,

wherein the pathogenic source is neutered in a disinfectant unit comprising:

a housing that is opaque to UV-C radiation/light; and

a chamber enclosed within the housing, wherein the chamber comprises:

(i) a chamber wall that is transparent to UV-C light;

(ii) a chamber inlet;

(iii) a chamber outlet;

(iv) a centralized inner bore having an interior chamber surface facing the inner bore;

(v) one or more UV-C light source positioned adjacent the interior surface; and

(vi) a helical air flow diverter centralized within the inner bore proximal the one or more UV-C light sources, wherein the helical air flow diverter comprises one or more rungs, wherein the helical airflow diverter creates a centrifugal force and a helical path for the airflow pathway as the airflow pathway proceeds from the housing inlet to the housing outlet, and

wherein varying the dosage and wavelength of the UV-C radiation involves:

(A) controlling one or more of the following parameters:

(i) intensity of UV-C emitted by the one or more UV-C light sources;

(ii) number, type and position of the one or more UV-C light sources; and

(iii) number of disinfectant units and/or number of chambers per disinfectant unit; and/or

(B) controlling the exposure time of the pathogenic source to the UV-C by adjusting or varying one or more of the following parameters:

(i) height of the chambers per disinfectant unit to thereby increase the height of the helical air flow diverter,

(ii) number of helical rungs,

(iii) a surface on the chamber wall with reflecting and/or irregular or crenulated walls to increase light ray reflections;

(iv) speed of the air flow through the device,

(v) a diameter of the helical rungs to control the proximity of the UV-C light source to the pathogens,

(vi) air flow velocity through the disinfectant unit(s); and

(vii) length of an air stream pathway through the disinfectant unit.

2. The method as claimed in claim 1 , wherein the pathogenic source is a virus.

3. The method as claimed in claim 1 , wherein the pathogenic source is a SARS-COV-2 virus.

4. The method as claimed in claim 1 , wherein an aliquot of the neutered pathogenic source is injected into an inhalation pump.

5. The method as claimed in claim 4 , wherein the aliquot of the neutered pathogenic source is injected into a first and a second upper compartment of the inhalation pump.

6. The method as claimed in claim 1 , wherein an aliquot of the neutered pathogenic source is injected into a syringe.

7. The method as claimed in claim 4 , wherein the inhalation pump comprises:

(a) a first half and a second half, wherein each half has a top compartment and an adjoining bottom compartment;

(b) a fill line associated with each half, the fill line having a septum on a bottom end and a top end that enters a central bore in the top compartment;

(c) each bottom compartment is filled with compressed air and has a moveable bottom end opposite to the adjoined top compartment; and

(d) each top compartment has a releasable cap at a top end opposite to the adjoined bottom compartment.

8. The method as claimed in claim 1 , further comprising administering an aliquot of the neutered pathogenic source to a patient by an intramuscular, subcutaneous, or intravenous injection.

9. The method as claimed in claim 1 , further comprising orally administering an aliquot of the neutered pathogenic source to a patient.

10. The method as claimed in claim 9 , wherein an aliquot of the neutered pathogenic source is administered in a tablet or a liquid form.

11. The method as claimed in claim 1 , further comprising administering an aliquot of the neutered pathogenic source to a patient through an inhalation, injection, or oral route.

12. The method as claimed in claim 7 , wherein the moveable bottom end is attachable to a syringe.

13. The method as claimed in claim 1 , wherein the immunogenic composition comprises a vaccine for promoting an immune response.